Status:
COMPLETED
Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary ...
Eligibility Criteria
Inclusion
- Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months
Exclusion
- Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
952 Patients enrolled
Trial Details
Trial ID
NCT01890993
Start Date
August 1 2013
End Date
June 1 2014
Last Update
May 21 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Paris La Défense Cedex, France, 92932
2
Mainz, Germany, 55127
3
Madrid, Spain, 28033
4
Crawley, United Kingdom, RH11 9RT